Janux Therapeutics (JANX) announced the appointment of Janeen Doyle as chief corporate and business development officer. She joins Janux from Flagship Pioneering, a life sciences-focused venture capital firm.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics Reports Increased Q1 Losses Amid R&D Expansion
- JANX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Janux Therapeutics price target lowered to $36 from $41 at Scotiabank
- Promising Pipeline and Strategic Advancements Justify Buy Rating for Janux Therapeutics Inc
- Positive Buy Rating for Janux Therapeutics Inc. Driven by Promising Clinical Data and Strong Financial Position